Verve Therapeutics, Inc. (VERV)

Verve Therapeutics, Inc. (VERV) scores 40 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $-19.02, representing a 41% margin of safety.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full VERV analysis on boothcheck